1
Inpharma 1242 - 17 Jun 2000 Indirect costs lower with raltitrexed Patients’ travel and time costs are significantly lower for those receiving raltitrexed for the treatment of advanced colorectal cancer than for those receiving fluorouracil plus folinic acid [leucovorin], report researchers in the UK. * Their calculations revealed that the total median per- patient cost was £206 for raltitrexed recipients and £342 for patients who received fluorouracil plus folinic acid. The respective mean costs per patient were £378 and £486. The researchers comment that this cost differential is largely due to fewer hospital visits required by raltitrexed recipients who receive treatment once every 21 days, compared with fluorouracil plus folinic acid recipients who are treated more frequently. The cost estimates are based on data collected prospectively from 270 patients who participated in an international clinical study; ** included were the costs of travel to and from hospital and time away from usual activities for treatment administration and the treatment of adverse events. * The study was funded by AstraZeneca Pharmaceuticals. ** In this study, patients were randomised to receive either raltitrexed 3 mg/m 2 as a 15-minute infusion once every 3 weeks, or fluorouracil 400 mg/m 2 as a 15-minute infusion plus folinic acid 200 mg/m 2 /day for 5 days every 4 weeks (Machover regimen). Sculpher M, et al. Costs incurred by patients in advanced colorectal cancer therapy: a comparison of raltitrexed and fluorouracil plus leucovorin. PharmacoEconomics 17: 361-370, Apr 2000 800810316 1 Inpharma 17 Jun 2000 No. 1242 1173-8324/10/1242-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Indirect costs lower with raltitrexed

  • View
    212

  • Download
    0

Embed Size (px)

Citation preview

Inpharma 1242 - 17 Jun 2000

Indirect costs lower with raltitrexedPatients’ travel and time costs are significantly lower

for those receiving raltitrexed for the treatment ofadvanced colorectal cancer than for those receivingfluorouracil plus folinic acid [leucovorin], reportresearchers in the UK.*

Their calculations revealed that the total median per-patient cost was £206 for raltitrexed recipients and £342for patients who received fluorouracil plus folinic acid.The respective mean costs per patient were £378 and£486. The researchers comment that this costdifferential is largely due to fewer hospital visits requiredby raltitrexed recipients who receive treatment onceevery 21 days, compared with fluorouracil plus folinicacid recipients who are treated more frequently.

The cost estimates are based on data collectedprospectively from 270 patients who participated in aninternational clinical study;** included were the costs oftravel to and from hospital and time away from usualactivities for treatment administration and the treatmentof adverse events.* The study was funded by AstraZeneca Pharmaceuticals.** In this study, patients were randomised to receive either raltitrexed3 mg/m2 as a 15-minute infusion once every 3 weeks, or fluorouracil400 mg/m2 as a 15-minute infusion plus folinic acid 200 mg/m2/day for5 days every 4 weeks (Machover regimen).

Sculpher M, et al. Costs incurred by patients in advanced colorectal cancertherapy: a comparison of raltitrexed and fluorouracil plus leucovorin.PharmacoEconomics 17: 361-370, Apr 2000 800810316

1

Inpharma 17 Jun 2000 No. 12421173-8324/10/1242-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved